The activities relating to the provision of bioanalytical tools and reagents, biological Defence and the life Sciences are maintained within the company Bertin Pharma.
Boost your gains
Montigny-le-Bretonneux may 10, 2017 – Bertin Pharma is input, the outcome of a competitive process, in exclusive negotiations with Amatsigroup in view of the sale of its business of pharmaceutical development (sites of Artigues-près-Bordeaux and Martillac) and with the group Oncodesign in view of the sale of its activities in pre-clinical studies and clinical exercised on other sites. With this proposed divestment of services in the sector of pharma/biotech, the Group CNIM intends to focus on strategic areas more in line with its core business of industrial in the field of energy, environment, defence and security. The quality and the ambition shown by the two buyers should also enable the activities and to the teams of Bertin Pharma concerned to register in prospects strong development.
The other members of staff acting primarily on bioanalytical tools and biodefense will continue their activities within Bertin Pharma, in close synergy with the team of Bertin Technologies.
This project, which is the subject of a procedure of information and consultation of staff representative bodies concerned, could be finalized during the summer of 2017.
Bertin Pharma, located in region Ile-de-France, Centre and Aquitaine, was born with the merger of several companies created or acquired between 1999 and 2013 (Ellipse Pharmaceuticals, SPI-Bio, Biotec Centre, IDPS, Johnson&Johnson Santé Beauté France).
Bertin Pharma, employs 125 people and generates a turnover of 16 million euros.
About Bertin Technologies : www.bertin-technologies.com
Bertin Technologies, a subsidiary of CNIM, is based on her long experience in innovation to develop, produce and market in the world systems and innovative equipment. With a turnover of close to 96 million euros in 2016, and 700 employees of which 2/3 are engineers and managers of high level, Bertin Technologies and its subsidiaries are involved in four major areas : systems and instrumentation, consultancy and engineering, information technology, pharma and biotech. Based in the paris region, the company operates at a global level.
About CNIM : www.cnim.com
CNIM designs and manufactures industrial complexes turnkey with high technological content and provides benefits expertise and services in the areas of Environment, Energy, Defence and High-technology. CNIM undertakes projects and sells equipment in the world. CNIM is based on a family shareholding stable, the guarantor of its development. The Group employs 2500 employees and a turnover in 2016 of 539,9 million euros, of which 54,6 % is made for export. CNIM is quoted on Euronext Paris.
Boost your gains